A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.
Clinical trial NCT06630871 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06630871
- Sponsor
- Fujian Medical University Union Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-01
- Primary completion
- 2026-10-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.